Brief: Cardiol Therapeutics Topline Results For Phase II Maveric-Pilot Study On CardiolRx Expected In Q2 2024
21/02/2024 14:36
Feb 21 (Reuters) - Cardiol Therapeutics Inc CRDL.TO :
* CARDIOL THERAPEUTICS: TOPLINE RESULTS FOR PHASE II
MAVERIC-PILOT
STUDY INVESTIGATING CARDIOLRX FOR RECURRENT PERICARDITIS
EXPECTED IN Q2 2024
Source text for Eikon: ID:n0001062993-24-003785
Further company coverage: CRDL.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cardiol Therapeutics
See all newsBrief: Cardiol Therapeutics Achieves Phase III Maveric Enrollment Target Ahead Of Schedule And Expands Pivotal Trial To Strengthen Assessment Of Cardiolrx's Efficacy
Brief: Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus
Brief: Cardiol Therapeutics Files For Mixed Shelf Offering Of Up To $150 Mln
Brief: Cardiol Therapeutics Initiated Pivotal Phase Iii Maveric Trial Of Cardiolrx In Recurrent Pericarditis
NASDAQ RESUMED AT 09:00 AM